Index removals put Ardent Health in focus

Ardent Health (ARDT) has been removed from several Russell growth benchmarks, including the Russell 3000 and Russell 2000 Growth Indexes. This type of change can prompt forced trading by index-linked funds.

For investors watching Ardent Health, these index changes raise questions about how index fund selling might intersect with the company’s fundamentals and recent share price performance.

Against this index backdrop, Ardent Health’s share price has been firming, with a 1-day share price return of 2.95%, a 7-day return of 7.77% and a year to date share price return of 17.25%. However, the 1-year total shareholder return is down 24.52%, suggesting that recent momentum contrasts with weaker longer term results.

If index reshuffles have you rethinking your watchlist, it could be an opportunity to broaden your search and check out 39 healthcare AI stocks

With Ardent Health trading at $10.13 and sitting about 22% below the average analyst price target of $12.32, the key question is simple: is this an underappreciated hospital operator, or is the market already pricing in future growth?

Most Popular Narrative: 19% Undervalued

Against Ardent Health’s last close at $10.13, the most followed narrative pegs fair value at $12.50, creating a valuation gap that hinges on operational execution and future earnings power.

The accelerated deployment of advanced technology, including AI-enabled scribe tools, virtual nursing, and digital wearables, improves clinical efficiency, reduces labor costs, limits nurse turnover, and streamlines workflow, all of which bolster operational efficiency and EBITDA margins.

The heart of this narrative is simple. Modest revenue growth, thicker margins, and a future earnings multiple that stays below the broader US healthcare sector. Want to see the exact earnings ramp and profitability assumptions that support that $12.50 fair value and the implied rerating in Ardent Health’s P/E.

Result: Fair Value of $12.50 (UNDERVALUED)

However, there is still meaningful risk that tighter Medicaid funding or renewed payer disputes could pressure Ardent Health’s margins and unsettle the current valuation narrative.

Another View: Ardent Health Through a Cash Flow Lens

While the most popular Ardent Health narrative leans on earnings multiples and a fair value of $12.50, the SWS DCF model points in a very different direction, with an estimated future cash flow value of $2.68 and the stock trading well above that level. For you, it raises a simple question: which story about $10.13 feels more convincing right now?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ardent Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 41 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Ardent Health clearly mixed, this is a moment to move fast, review the data yourself, and weigh up 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Ardent Health?

If Ardent Health is on your radar, do not stop there. Widen your opportunity set with a few focused stock ideas that could sharpen your next move.

• Target resilience by scanning companies that prioritize financial strength using the solid balance sheet and fundamentals stocks screener (47 results)
• Hunt for mispriced quality by reviewing the screener containing 19 high quality undiscovered gems before the crowd catches on.
• Prioritize consistency and capital protection by filtering for 73 resilient stocks with low risk scores that might help steady your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.